Saturday 17 October 2026
Export ELOX’s income statement to Excel — free account
Senesco Technologies Inc.
ELOX Healthcare Biotechnology
Senesco Technologies Inc.’s revenue for fiscal 2024 (year ended December 2024) was $6.4 million. In the quarter to June 2026, EPS grew 87.7% and free cash flow fell 144.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
13.03
0.67
−4.89%
Follow ELOX
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
— | 0.31 | 0.53 | 3.74 |
Net Debt/EBITDA |
0.00 | 0.00 | 1.68 | 13.95 | |
Debt/Assets |
0.00% | 18.98% | 0.00% | 0.00% | |
Debt/Equity |
— | (0.08) | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | — | 1.45 | 1.06 | |
Capex/Depreciation |
0.00 | — | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(5.05) | — | (1.24) | (0.71) | |
Cash per Share |
0.00 | 0.00 | 1.45 | 9.13 | |
Shareholders Equity per Share |
0.00 | 0.00 | (1.73) | 6.84 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | (1.73) | 6.84 | |
Free Cash Flow |
(1.75) | — | (5.45) | (4.79) | |
Working Capital |
— | (11.91) | (7.58) | 46.42 | |
Net Current Asset Value |
— | (11.91) | (7.58) | 46.42 | |
| Other line items | |||||
Quick Ratio |
— | 0.28 | 0.40 | 3.65 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(5.05) | — | (1.24) | (0.71) | |
Capex per Share |
0.00 | — | 0.00 | 0.00 | |
Average Payables |
— | 2.57 | 3.07 | 3.08 | |
Average Assets |
3.00 | 6.24 | 7.25 | 34.72 | |
Average Common Equity |
— | (14.10) | (13.09) | 13.19 |
Columns are period end dates